Precision Vaccinations

 → August 9th, 2020

Eliminating fake vaccine news with pharmacist, nurse, and physician review.

Aug 9 • 2:52 pm CDT

The Kingdom of Saudi Arabia announced on August 9, 2020, it will soon begin a late-stage, Phase 3 clinical trial of around 5,000 people for COVID-19 disease preventive vaccine known as Ad5-nCoV, reported Reuters. The Ad5-nCoV vaccine candidate is a genetically engineered vaccine candidate with the replication-defective adenovirus type 5 as the vector to express SARS-CoV-2 spike protein.

This CanSino’s vaccine, which was co-developed with China’s military research unit, was reported to be safe and induced immune responses in most participants in a limited study.

Aug 9 • 9:38 am CDT

A new study by researchers at the University of Chicago and Duke University published in Science Advances on August 7, 2020, demonstrates the potential for an intranasal vaccine platform, using self-assembling peptide nanofibers tagged with antigens to prime the immune system against a potential virus invasion.

This research showed that these nanofibers can induce an immune response and activate T cells without the use of additional adjuvants, which can induce inflammation and are associated with common vaccine side effects, like soreness at the injection site or low-grade fever.

'Thus, self-assembling peptide nanofiber vaccines may represent a novel, needle- and adjuvant-free means of eliciting protective immunity against fungal and bacterial infections at the skin and mucosal barrier surfaces,' concluded these researchers.

Aug 8 • 6:29 pm CDT

The U.S. FDA has issued 207 coronavirus diagnostic tests authorizations, as of August 7, 2020, which include 168 molecular tests, 37 antibody tests, and 2 antigen tests.

COVID-19 Antibody (IgG), Immunoassay tests are sponsored by UltaLabs.

Aug 8 • 9:21 am CDT

A study published online on August 6, 2020, found the NVX-CoV2373/Matrix-M1 vaccine candidate was well-tolerated and elicited robust immune responses 4-fold higher than the mean observed in COVID-19 convalescent serum from participants with clinical symptoms requiring medical care and induced CD4+ T-cell responses biased toward a Th1 phenotype.

'These findings suggest that the Novavax's NVX-CoV2373 vaccine may confer protection and support transition to efficacy evaluations to test this hypothesis.'

Aug 8 • 8:06 am CDT

The U.S. CDC's new data indicates there have been 65,756,307 completed tests to confirm if a person has a SARS-CoV-2 infection. As of August 7, 2020, the national infection rate was about 9%.

For more articles, try our search.